Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
- 15 January 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (2), 723-730
- https://doi.org/10.1158/1078-0432.ccr-08-0596
Abstract
Purpose: To assess the feasibility of administering XRP6258, a new taxane with a low affinity for the multidrug resistance 1 protein, as a 1-hour i.v. infusion every 3 weeks. The study also sought to determine the maximum tolerated dose and the recommended dose, to describe the pharmacokinetic (PK) behavior of the compound, and to seek preliminary evidence of anticancer activity. Experimental Design: Twenty-five patients with advanced solid malignancies were treated with 102 courses of XRP6258 at four dose levels ranging from 10 to 25 mg/m2. Dose escalation was based on the occurrence of dose-limiting toxicity (DLT) at each dose level, provided that PK variables were favorable. The maximum tolerated dose was defined as the dose at which at least two patients developed a DLT at the first course. Results: Neutropenia was the principal DLT, with one patient experiencing febrile neutropenia and two others showing prolonged grade 4 neutropenia at the 25 mg/m2 dose level. Nonhematologic toxicities, including nausea, vomiting, diarrhea, neurotoxicity, and fatigue, were generally mild to moderate in severity. XRP6258 exhibited dose-proportional PK, a triphasic elimination profile, a long terminal half-life (77.3 hours), a high clearance (mean CL, 53.5 L/h), and a large volume of distribution (mean Vss, 2,034 L/m2). Objective antitumor activity included partial responses in two patients with metastatic prostate carcinoma, one unconfirmed partial response, and two minor responses. Conclusion: The recommended phase II dose of XRP6258 on this schedule is 20 mg/m2. The general tolerability and encouraging antitumor activity in taxane-refractory patients warrant further evaluations of XRP6258.Keywords
This publication has 12 references indexed in Scilit:
- Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumorsCancer Chemotherapy and Pharmacology, 2006
- Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor ActivityClinical Cancer Research, 2006
- Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and ratsBritish Journal of Pharmacology, 2003
- Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001JNCI Journal of the National Cancer Institute, 2002
- Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than PaclitaxelJournal of Clinical Oncology, 2001
- The blood-brain barrier and oncology: new insights into function and modulationCancer Treatment Reviews, 2000
- The taxoids: paclitaxel and docetaxelThe Lancet, 1994
- Physiological Parameters in Laboratory Animals and HumansPharmaceutical Research, 1993
- Structure and Function of P-Glycoprotein in Normal Liver and Small IntestineAdvances in Pharmacology, 1993
- Kinetics of pharmacologic response I. Proposed relationships between response and drug concentration in the intact animal and manJournal of Theoretical Biology, 1968